Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

PHASE3RecruitingINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

May 6, 2025

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2030

Conditions
NSCLC (Non-small Cell Lung Cancer)Non-Small Cell Lung CancerNSCLCNSCLC (Non-small Cell Lung Carcinoma)NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
DRUG

daraxonrasib

oral tablets

DRUG

docetaxel

intravenous (IV) infusion

Trial Locations (44)

100

RECRUITING

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung

110

RECRUITING

Taipei Medical University Hospital, Taipei

8800

RECRUITING

AZ Delta, Roeselare

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10461

RECRUITING

Montefiore Medical Center, The Bronx

22031

RECRUITING

Virginia Cancer Specialists, Fairfax

32955

RECRUITING

Cancer Care Centers of Breevard, Rockledge

33322

RECRUITING

BRCR Global, Plantation

33401

RECRUITING

Florida Cancer Specialists & Research Institute - East, West Palm Beach

33705

RECRUITING

Florida Cancer Specialists & Research Institute - North, St. Petersburg

33901

RECRUITING

Florida Cancer Specialists & Research Institute - South, Fort Myers

34376

RECRUITING

LKI Lungenfachklinik Immenhausen, Immenhausen

34994

RECRUITING

Cleveland Clinic Martin North, Stuart

35243

RECRUITING

Alabama Oncology, Birmingham

37203

RECRUITING

SCRI Oncology Partners - Tennessee, Nashville

43537

RECRUITING

Taylor Cancer Research Center, Maumee

45220

RECRUITING

TriHealth Cancer & Blood Institute Research, Cincinnati

48201

RECRUITING

Karmanos Cancer Institute, Detroit

59102

RECRUITING

St. Vincent Frontier Cancer Center, Billings

63110

RECRUITING

Washington University School of Medicine - Siteman Cancer Center, St Louis

67091

RECRUITING

CHU Strasbourg - Nouvel Hôpital Civil, Strasbourg

75018

RECRUITING

Hôpital Bichat - Claude Bernard, Paris

75251

RECRUITING

Texas Oncology Dallas, Dallas

77030

RECRUITING

MD Anderson Cancer Center, Houston

77380

RECRUITING

Texas Oncology - Gulf Coast, The Woodlands

78745

RECRUITING

Texas Oncology - South Austin, Austin

84106

RECRUITING

Utah Cancer Specialists, Salt Lake City

94000

RECRUITING

Centre Hospitalier Intercommunal de Créteil, Créteil

97401

RECRUITING

Oncology Associates of Oregon PC, Eugene

119074

RECRUITING

National University Hospital, Singapore

Unknown

RECRUITING

Hong Kong United Oncology Centre, Hong Kong

464-8681

RECRUITING

Aichi Cancer Center Hospital, Nagoya

470-1192

RECRUITING

Fujita Health University Hospital, Toyoake-shi

791-0280

RECRUITING

NHO Shikoku Cancer Center, Matsuyama

003-0804

RECRUITING

National Hospital Organization Hokkaido Cancer Center, Sapporo

673-8558

RECRUITING

Hyogo Cancer Center, Akashi

241-8515

RECRUITING

Kanagawa Cancer Center, Yokohama

634-8522

RECRUITING

Nara Medical University Hospital, Kashihara-shi

951-8566

RECRUITING

Niigata Cancer Center, Niigata

589-8511

RECRUITING

Kindai University Hospital, Osakasayama-shi

104-0045

RECRUITING

National Cancer Center Hospital, Chuo Ku

135-8550

RECRUITING

Cancer Institute Hospital of JFCR, Koto-Ku

1066 CX

RECRUITING

Antoni van Leeuwenhoek, Amsterdam

00909

RECRUITING

Pan American Center for Oncology Trials, San Juan

All Listed Sponsors
lead

Revolution Medicines, Inc.

INDUSTRY